Show simple item record

The relationship between gut microbiota and short chain fatty acids in the renal calcium oxalate stones disease

dc.contributor.authorLiu, Yu
dc.contributor.authorJin, Xi
dc.contributor.authorHong, Hyokyoung G.
dc.contributor.authorXiang, Liyuan
dc.contributor.authorJiang, Qingyao
dc.contributor.authorMa, Yucheng
dc.contributor.authorChen, Zude
dc.contributor.authorCheng, Liang
dc.contributor.authorJian, Zhongyu
dc.contributor.authorWei, Zhitao
dc.contributor.authorAi, Jianzhong
dc.contributor.authorQi, Shiqian
dc.contributor.authorSun, Qun
dc.contributor.authorLi, Hong
dc.contributor.authorLi, Yi
dc.contributor.authorWang, Kunjie
dc.date.accessioned2020-09-02T14:58:28Z
dc.date.availableWITHHELD_12_MONTHS
dc.date.available2020-09-02T14:58:28Z
dc.date.issued2020-08
dc.identifier.citationLiu, Yu; Jin, Xi; Hong, Hyokyoung G.; Xiang, Liyuan; Jiang, Qingyao; Ma, Yucheng; Chen, Zude; Cheng, Liang; Jian, Zhongyu; Wei, Zhitao; Ai, Jianzhong; Qi, Shiqian; Sun, Qun; Li, Hong; Li, Yi; Wang, Kunjie (2020). "The relationship between gut microbiota and short chain fatty acids in the renal calcium oxalate stones disease." The FASEB Journal (8): 11200-11214.
dc.identifier.issn0892-6638
dc.identifier.issn1530-6860
dc.identifier.urihttps://hdl.handle.net/2027.42/156429
dc.description.abstractThe relationship of gut microbiota and calcium oxalate stone has been limited investigated, especially with no study of gut microbiota and short chain fatty acids (SCFAs) in nephrolithiasis. We provided Sprague Dawley rats of renal calcium oxalate stones with antibiotics and examined the renal crystals deposition. We also performed a case‐control study by analyzing 16S rRNA microbial profiling, shotgun metagenomics and SCFAs in 153 fecal samples from non‐kidney stone (NS) controls, patients with occasional renal calcium oxalate stones (OS) and patients with recurrent stones (RS). Antibiotics reduced bacterial load in feces and could promote the formation of renal calcium crystals in model rats. In addition, both OS and RS patients exhibited higher fecal microbial diversity than NS controls. Several SCFAs‐producing gut bacteria, as well as metabolic pathways associated with SCFAs production, were considerably lower in the gut microbiota among the kidney stone patients compared with the NS controls. Representation of genes involved in oxalate degradation showed no significance difference among groups. However, fecal acetic acid concentration was the highest in RS patients with high level of urinary oxalate, which was positively correlated with genes involvement in oxalate synthesis. Administration of SCFAs reduced renal crystals. These results shed new light on bacteria and SCFAs, which may promote the development of treatment strategy in nephrolithiasis.
dc.publisherWiley Periodicals, Inc.
dc.subject.otherrenal calcium oxalate stones
dc.subject.othershotgun metagenomics
dc.subject.othersgut microbiota
dc.subject.other16s Rrna
dc.subject.othershort chain fatty acids
dc.titleThe relationship between gut microbiota and short chain fatty acids in the renal calcium oxalate stones disease
dc.typeArticle
dc.rights.robotsIndexNoFollow
dc.subject.hlbsecondlevelBiology
dc.subject.hlbtoplevelScience
dc.description.peerreviewedPeer Reviewed
dc.description.bitstreamurlhttp://deepblue.lib.umich.edu/bitstream/2027.42/156429/3/fsb220780.pdfen_US
dc.description.bitstreamurlhttp://deepblue.lib.umich.edu/bitstream/2027.42/156429/2/fsb220780-sup-0002-TableS1-S6.pdfen_US
dc.description.bitstreamurlhttp://deepblue.lib.umich.edu/bitstream/2027.42/156429/1/fsb220780_am.pdfen_US
dc.identifier.doi10.1096/fj.202000786R
dc.identifier.sourceThe FASEB Journal
dc.identifier.citedreferenceScheiman J, Luber JM, Chavkin TA, et al. Meta‐omics analysis of elite athletes identifies a performance‐enhancing microbe that functions via lactate metabolism. Nat Med. 2019; 25: 1104 ‐ 1109.
dc.identifier.citedreferenceAmato M, Lusini ML, Nelli F. Epidemiology of nephrolithiasis today. Urol Int. 2004; 72 ( Suppl 1 ): 1 ‐ 5.
dc.identifier.citedreferenceLiu Y, Chen Y, Liao B, et al. Epidemiology of urolithiasis in Asia. Asian J Urol. 2018; 5: 205 ‐ 214.
dc.identifier.citedreferenceSadaf H, Raza SI, Hassan SW. Role of gut microbiota against calcium oxalate. Microb Pathog. 2017; 109: 287 ‐ 291.
dc.identifier.citedreferenceTasian GE, Jemielita T, Goldfarb DS, et al. Oral antibiotic exposure and kidney stone disease. J Am Soc Nephrol. 2018; 29: 1731 ‐ 1740.
dc.identifier.citedreferenceAllison MJ, Dawson KA, Mayberry WR, Foss JG. Oxalobacter formigenes gen. nov., sp. nov.: oxalate‐degrading anaerobes that inhabit the gastrointestinal tract. Arch Microbiol. 1985; 141: 1 ‐ 7.
dc.identifier.citedreferenceTavasoli S, Alebouyeh M, Naji M, et al. Association of intestinal oxalate‐degrading bacteria with recurrent calcium kidney stone formation and hyperoxaluria: a case‐control study. BJU Int. 2020; 125: 133 ‐ 143.
dc.identifier.citedreferenceMilliner D, Hoppe B, Groothoff J. A randomised Phase II/III study to evaluate the efficacy and safety of orally administered Oxalobacter formigenes to treat primary hyperoxaluria. Urolithiasis. 2018; 46: 313 ‐ 323.
dc.identifier.citedreferenceKoh A, De Vadder F, Kovatcheva‐Datchary P, Backhed F. From dietary fiber to host physiology: short‐chain fatty acids as key bacterial metabolites. Cell. 2016; 165: 1332 ‐ 1345.
dc.identifier.citedreferenceLi L, Ma L, Fu P. Gut microbiota‐derived short‐chain fatty acids and kidney diseases. Drug Des Devel Ther. 2017; 11: 3531 ‐ 3542.
dc.identifier.citedreferenceVaziri ND, Liu S‐M, Lau WL, et al. High amylose resistant starch diet ameliorates oxidative stress, inflammation, and progression of chronic kidney disease. PLoS One. 2014; 9: e114881.
dc.identifier.citedreferenceKhan S, Jena G. Sodium butyrate, a HDAC inhibitor ameliorates eNOS, iNOS and TGF‐β1‐induced fibrogenesis, apoptosis and DNA damage in the kidney of juvenile diabetic rats. Food Chem Toxicol. 2014; 73: 127 ‐ 139.
dc.identifier.citedreferenceXiang S, Zhou J, Li J, et al. Antilithic effects of extracts from different polarity fractions of Desmodium styracifolium on experimentally induced urolithiasis in rats. Urolithiasis. 2015; 43: 433 ‐ 439.
dc.identifier.citedreferenceYamamoto K, Ishigami M, Honda T, et al. Influence of proton pump inhibitors on microbiota in chronic liver disease patients. Hep Intl. 2019; 13: 234 ‐ 244.
dc.identifier.citedreferenceOliphant K, Allen‐Vercoe E. Macronutrient metabolism by the human gut microbiome: major fermentation by‐products and their impact on host health. Microbiome. 2019; 7: 91.
dc.identifier.citedreferenceCanfora EE, Meex RCR, Venema K, Blaak EE. Gut microbial metabolites in obesity, NAFLD and T2DM. Nat Rev Endocrinol. 2019; 15 ( 5 ): 261 ‐ 273. https://doi.org/10.1038/s41574‐019‐0156‐z
dc.identifier.citedreferenceSpiljar M, Merkler D, Trajkovski M. The immune system bridges the gut microbiota with systemic energy homeostasis: focus on TLRs, mucosal barrier, and SCFAs. Front Immunol. 2017; 8: 1353.
dc.identifier.citedreferenceJuanola O, Ferrusquía‐Acosta J, García‐Villalba R, et al. Circulating levels of butyrate are inversely related to portal hypertension, endotoxemia, and systemic inflammation in patients with cirrhosis. FASEB J. 2019; 33: 11595 ‐ 11605.
dc.identifier.citedreferenceBultman SJ. Bacterial butyrate prevents atherosclerosis. Nat Microbiol. 2018; 3 ( 12 ): 1332 ‐ 1333. https://doi.org/10.1038/s41564‐018‐0299‐z
dc.identifier.citedreferenceHeaney LM, Davies OG, Selby NM. Gut microbial metabolites as mediators of renal disease: do short‐chain fatty acids offer some hope? Future Sci OA. 2019; 5: Fso384.
dc.identifier.citedreferenceLee PC, Lee SY, Chang HN. Succinic acid production by Anaerobiospirillum succiniciproducens ATCC 29305 growing on galactose, galactose/glucose, and galactose/lactose. J Microbiol Biotechnol. 2008; 18: 1792 ‐ 1796.
dc.identifier.citedreferenceLouis P, Hold GL, Flint HJ. The gut microbiota, bacterial metabolites and colorectal cancer. Nat Rev Microbiol. 2014; 12: 661 ‐ 672.
dc.identifier.citedreferencePukall R, Lapidus A, Glavina Del Rio T, et al. Complete genome sequence of Conexibacter woesei type strain (ID131577). Stand Genomic Sci. 2010; 2: 212 ‐ 219.
dc.identifier.citedreferenceNishino K, Nishida A, Inoue R, et al. Analysis of endoscopic brush samples identified mucosa‐associated dysbiosis in inflammatory bowel disease. J Gastroenterol. 2018; 53: 95 ‐ 106.
dc.identifier.citedreferenceMoludi J, Alizadeh M, Lotfi Yagin N, et al. New insights on atherosclerosis: a cross‐talk between endocannabinoid systems with gut microbiota. J Cardiovascular Thorac Res. 2018; 10: 129 ‐ 137.
dc.identifier.citedreferenceFranco‐de‐Moraes AC, de Almeida‐Pititto B, da Rocha Fernandes G, Gomes EP, da Costa Pereira A, Ferreira SRG. Worse inflammatory profile in omnivores than in vegetarians associates with the gut microbiota composition. Diabetol Metab Syndr. 2017; 9: 62.
dc.identifier.citedreferenceAcharya A, Chan Y, Kheur S, et al. Salivary microbiome of an urban Indian cohort and patterns linked to subclinical inflammation. Oral Dis. 2017; 23: 926 ‐ 940.
dc.identifier.citedreferenceKaufman DW, Kelly JP, Curhan GC, et al. Oxalobacter formigenes may reduce the risk of calcium oxalate kidney stones. J Am Soc Nephrol. 2008; 19: 1197 ‐ 1203.
dc.identifier.citedreferenceMiller AW, Choy D, Penniston KL, Lange D. Inhibition of urinary stone disease by a multi‐species bacterial network ensures healthy oxalate homeostasis. Kidney Int. 2019; 96: 180 ‐ 188.
dc.identifier.citedreferenceTicinesi A, Milani C, Guerra A, et al. Understanding the gut‐kidney axis in nephrolithiasis: an analysis of the gut microbiota composition and functionality of stone formers. Gut. 2018; 67: 2097 ‐ 2106.
dc.identifier.citedreferenceSuryavanshi MV, Bhute SS, Jadhav SD, Bhatia MS, Gune RP, Shouche YS. Hyperoxaluria leads to dysbiosis and drives selective enrichment of oxalate metabolizing bacterial species in recurrent kidney stone endures. Sci Rep. 2016; 6: 34712.
dc.identifier.citedreferenceTang R, Jiang Y, Tan A, et al. 16S rRNA gene sequencing reveals altered composition of gut microbiota in individuals with kidney stones. Urolithiasis. 2018; 46: 503 ‐ 514.
dc.identifier.citedreferenceSuryavanshi MV, Bhute SS, Gune RP, Shouche YS. Functional eubacteria species along with trans‐domain gut inhabitants favour dysgenic diversity in oxalate stone disease. Sci Rep. 2018; 8: 16598.
dc.owningcollnameInterdisciplinary and Peer-Reviewed


Files in this item

Show simple item record

Remediation of Harmful Language

The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.

Accessibility

If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.